Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

Inclusion Criteria:

- Histologically confirmed classical Hodgkin Lymphoma or Lymphocyte Predominant Hodgkin
Lymphoma with progressive disease during or at the end of the previous therapy, as
defined by the IWG criteria.

- Patient must have nodular sclerosing, lymphocyte depleted, or mixed cellularity
Hodgkin Lymphoma (Classical Hodgkin Lymphoma), or Lymphocyte predominant Hodgkin
Lymphoma.

- Baseline measurements and evaluations must be obtained within 4 weeks of registration
to the study.

- Abnormal PET scans will not constitute evaluable disease, unless verified by CT scan
or other appropriate imaging.

- A clearly defined, bidimensionally measurable lymph node or tumor mass measuring at
least 2 cm in diameter on a CT scan.

- Patient should have had at least one line of prior chemotherapy. Patients relapsing
after treatment with radiation therapy alone are not eligible.

- Age > than or equal to 18 years.

- Both men and women and members of all races and ethnic groups are eligible for this
trial.

- Women must not be pregnant or breast-feeding due to lack of information about the
safety of administration of Temsirolimus in pregnant and lactating patients. All
females of childbearing potential must have a blood test or urine study within 2
weeks prior to registration to rule out pregnancy.

- Women of childbearing potential and sexually active males are strongly advised to use
an accepted and effective method of pregnancy prevention.

- Patient must have a SWOG performance status between 0-2.

- Patient must have no prior treatment with an m-TOR inhibitor.

- Patient must not have active infections at the time of registration.

- Laboratory studies should be obtained within two weeks of study registration except
where noted otherwise. Allowable laboratory values are listed below:

- Absolute neutrophil count > than or equal 1,000/mm3

- Hemoglobin > than or equal 8 gm/dL

- Platelets > than or equal 75,000/mm3

- Serum creatinine < than or equal to two times the upper limit of normal. Creatinine
should be measured within seven days of registration.

- Total serum bilirubin < than or equal to ≤ 1.5 times the upper limit of normal.
Total bilirubin should be measured within seven days of registration.

- AST (SGOT) < than or equal to 3 times the upper limit of normal.

- ALT (SGPT) < than or equal to 3 times the upper limit of normal.

- Fasting total cholesterol < than or equal to 350 mg/dL.

- Fasting triglyceride level < than or equal to 400 mg/dL.

- Patient must have a life expectancy of three months.

Exclusion Criteria:

- Patient must not have received prior allogeneic stem cell transplantation. Prior
autologous stem cell transplantation more than six months prior to registration is
acceptable.

- Patient must not have received prior chemotherapy, biologic therapy or radiation
within three weeks prior to registration, and should have recovered from toxicities
of prior therapy (to Grade 0 or 1).

- Patient must not have evidence of active CNS disease.

- Patient must not have an uncontrolled comorbid disease, including hyperlipidemia,
hypertriglyceridemia, diabetes mellitus, symptomatic congestive heart failure,
unstable angina pectoris, or cardiac arrhythmia

- Patient must not have a psychiatric illness or social situation that would limit
compliance with study requirements.

- Patient must have a life expectancy of three months.